Ocular Therapeutix announces first patient dosed in phase 1 clinical trial of OTX-CSI to treat dry eye disease
“We are pleased to be advancing OTX-CSI in the chronic treatment of dry eye disease,” said Michael Goldstein, MD, MBA, Chief Medical Officer. “We believe that the intracanalicular
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.